Gary Romano
About Gary Romano
Gary Romano - Chief Medical Officer
Gary Romano holds the distinguished title of Chief Medical Officer. He has a robust background in neurodegenerative disease research and clinical development. His career spans multiple high-ranking positions in reputable organizations, contributing significantly to advancements in medical science, particularly in neurology.
Gary Romano's Education and Expertise
Gary Romano earned a B.S. in Biology from Trinity College. He holds a Ph.D. in Molecular Neurobiology from Rockefeller University and an M.D. from The Johns Hopkins University School of Medicine. He completed his medical internship, neurology residency, and a neuromuscular fellowship at the University of Pennsylvania. His multidisciplinary education forms a strong foundation for his career in neurodegenerative disease research and clinical development.
Gary Romano's Background in Neurodegenerative Diseases
Gary Romano has a notable background in neurodegenerative diseases, having served in pivotal roles at Janssen and Merck. At Janssen, he spent over five years overseeing the neurodegenerative disease portfolio, holding titles such as Deputy Leader, Neurodegenerative Disease Area, and Head of Development. Additionally, he served as Head of Neuroscience Biomarkers and Head of Early Clinical Development. At Merck, he contributed as Alzheimer’s Disease Therapeutic Area Group Co-Leader and Leader, Neuroscience Experimental Medicine.
Gary Romano's Leadership Roles in Alzheimer's Disease Initiatives
Gary Romano has actively contributed to Alzheimer's disease research and initiatives. He served on the executive committee of the Innovative Medicines Initiative – European Prevention of Alzheimer’s Dementia (EPAD). Furthermore, he has held the position of industry co-chair of the Critical Path Institute Coalition Against Alzheimer’s Disease, underscoring his commitment to advancing the understanding and treatment of Alzheimer's.
Gary Romano's Board Memberships and Academic Role
Gary Romano serves on the board of directors of the ALS Hope Foundation, aligning with his ongoing commitment to neurodegenerative disease research and advocacy. He is also an adjunct member of the neurology department at the Lewis Katz School of Medicine at Temple University, contributing to academic advancements in neurology and supporting the education of future medical professionals.